| First Author | Kraev A | Year | 2018 |
| Journal | J Card Fail | Volume | 24 |
| Issue | 2 | Pages | 115-125 |
| PubMed ID | 29325795 | Mgi Jnum | J:339014 |
| Mgi Id | MGI:7519246 | Doi | 10.1016/j.cardfail.2017.12.009 |
| Citation | Kraev A (2018) Insertional Mutagenesis Confounds the Mechanism of the Morbid Phenotype of a PLN(R9C) Transgenic Mouse Line. J Card Fail 24(2):115-125 |
| abstractText | BACKGROUND: A mouse line with heterozygous transgenic expression of phospholamban carrying a substitution of cysteine for arginine 9 (TgPLN(R9C)) under the control of alpha-myosin heavy chain (alphaMHC) promoter features dilated cardiomyopathy, heart failure, and premature death. METHODS AND RESULTS: Determination of transgene chromosomal localization by conventional methods shows that in this line the transgenic array of 13 PLN(R9C) expression cassettes, arranged in a head-to-tail tandem orientation, have integrated into the bidirectional promoter of the alphaMHC (Myh6) gene and the gene for the regulatory noncoding RNA Myheart (Mhrt), both of which are known to be involved in cardiac development and pathology. Expression of the noncoding RNA Mhrt in TgPLN(R9C) mice exhibits profound deregulation, despite the presence of the second, intact allele. CONCLUSIONS: The TgPLN(R9C) mouse strain is, in the best case, a functionally ambiguous phenocopy of the human PLN(R9C) heterozygote, because a similar constellation of genetically programmed events can not occur in a patient. Publications featuring "cardiac-specific overexpression" are focused on the phenotype and typically forgo the definition of the transgene integration site or transgene temporal expression profile, so caution should be exercised in attributing clinical relevance to pathologic phenomena observed in alphaMHC-driven transgenes. |
